The Cell and Gene Therapy CDMO Market Is Entering Its Commercial Era — What It Means for Sponsors and Manufacturers

For much of the past decade, the cell and gene therapy sector has been defined by scientific ambition and clinical milestones — first-in-human studies, breakthrough designations, and headline-grabbing approvals that validated the premise of genetically engineered medicine. But the conversation among CDMO executives and biopharma supply chain leaders has shifted perceptibly. The question is no longer whether these therapies work. It is whether manufacturers can produce them reliably, at scale, and within the cost structures that commercial markets demand. That transition — from clinical experimentation to commercial readiness — is the defining strategic pressure of this market cycle.

Nexvora Intelligence estimates the global cell and gene therapy CDMO market at $7.8–8.6 billion in 2025, with a growing proportion of that revenue now tied to late-stage clinical and commercial programs rather than early discovery and feasibility work. This compositional shift matters enormously. Commercial and late-stage contracts carry different economics, different regulatory scrutiny, and fundamentally different consequences when something goes wrong. CDMOs that built their reputations on flexible, small-batch clinical work are being forced to re-examine whether their operational cultures, quality systems, and facility architectures are genuinely suited to long-term supply obligations. Those that can credibly answer yes are capturing disproportionate contract value.

Nexvora's modeled projections place the global cell and gene therapy CDMO market on a trajectory to reach $24–31 billion by 2032, representing a compound annual growth rate of approximately 17%–21% from 2025. Those are striking figures by any measure, and it is worth understanding what actually drives them rather than treating the headline CAGR as an abstraction. The primary engine is pipeline conversion: the steady advancement of clinical-stage programs into pivotal trials and, ultimately, regulatory review. Each successful approval typically unlocks a long-term commercial manufacturing agreement that generates substantially more revenue per program than the clinical-stage work that preceded it.

A secondary driver is contract scope expansion. Sponsors entering commercial manufacturing relationships are increasingly unwilling to fragment their supply chains across multiple vendors for plasmid DNA, viral vector production, cell processing, analytical testing, and fill-finish. That preference for integration means that CDMOs capable of offering a genuine end-to-end service model can capture a much larger revenue footprint per program. Nexvora's assessment suggests that integrated CDMO models are gaining measurable market share over point-solution providers, particularly for programs with complex regulatory histories or ambitious global commercialization plans. The implication for CDMO business development teams is clear: demonstrating breadth without sacrificing depth is now a core competitive requirement.

Pricing dynamics are equally nuanced. For complex, late-stage, and commercial-ready manufacturing programs, pricing has remained resilient — sponsors simply cannot afford to optimize on cost when a batch failure could strand thousands of patients. However, early-stage capacity is becoming meaningfully more competitive as a wave of facility expansions, initiated during the capital-abundant years of 2020–2022, has come online and bidding for Phase I and II programs has intensified. CDMOs are navigating a bifurcated pricing environment, and their ability to migrate early-stage sponsors into longer, higher-value commercial relationships will define their revenue quality over the next several years.

Viral vector manufacturing — encompassing lentiviral, adeno-associated virus (AAV), and adenoviral platforms — is simultaneously the most valuable and most operationally constrained service area in the entire CDMO landscape. Nexvora estimates that viral vector services represent approximately 35%–42% of 2025 global market value across process development, GMP manufacturing, and analytical support. That concentration is not coincidental. Viral vectors are the delivery mechanism for a broad swath of gene therapy and CAR-T programs, and their manufacturing is genuinely difficult: yield is variable, characterization is complex, and regulatory expectations around identity, purity, and potency continue to evolve.

The strategic consequence of this constraint is that viral vector manufacturing capacity functions almost like a rate-limiting valve for the broader cell and gene therapy pipeline. Programs that cannot secure vector supply cannot progress. CDMOs with validated, high-titer production platforms and established regulatory track records in vector manufacturing have significant leverage in contract negotiations, and Nexvora's assessment is that this leverage is unlikely to erode quickly even as new capacity investments come online. The analytical complexity associated with vector characterization — residual host cell protein quantification, capsid full/empty ratio determination, genomic integrity assessment — creates a capability moat that takes years rather than months to establish.

For sponsor companies evaluating CDMO partners for vector work, the differentiating questions are increasingly granular: What is the CDMO's batch success rate across comparable vector serotypes? How deep is their internal analytical development capability versus what is outsourced? What is their actual experience with comparability studies following process changes? These are not questions that can be answered convincingly with marketing materials. They require audit data, regulatory submission histories, and candid conversations with reference clients — exactly the kind of due diligence that the most sophisticated sponsors are now conducting before signing any vector manufacturing agreement.

Cell therapy manufacturing is undergoing a quieter but equally consequential transformation. The early days of autologous CAR-T manufacturing were defined by highly manual, patient-specific workflows — each batch essentially a one-of-a-kind production run with limited process standardization. That model was clinically necessary but operationally fragile, and it is now giving way to a more structured approach centered on semi-automated, closed-system workflows that reduce operator-introduced variability, improve batch-to-batch consistency, and lower the contamination risk inherent in open-process manufacturing.

This shift is being driven by several converging forces. First, regulatory agencies are signaling increasing interest in process controls and real-time release strategies for cell therapies, which rewards manufacturers who have invested in in-line monitoring and automated process documentation. Second, the emergence of allogeneic cell therapy platforms — where a single donor-derived product can theoretically treat multiple patients — demands a manufacturing paradigm much closer to conventional biologics than to autologous personalized medicine. Allogeneic approaches require CDMOs to think about scalability from the earliest stages of process development, rather than retrofitting commercial-scale thinking onto a clinical-scale process designed for single-patient batches.

Next-generation immune cell therapy programs, including natural killer cell and gamma-delta T cell platforms, are adding further complexity to the cell therapy CDMO landscape. These modalities require distinct expansion protocols, cryopreservation strategies, and release assay panels, and few CDMOs have developed deep process expertise across all of them. Nexvora's view is that cell therapy CDMOs will increasingly need to make deliberate platform specialization choices rather than attempting to serve every modality with equal competence. The sponsors developing the most scientifically complex programs will preferentially choose partners who demonstrate genuine modality-specific expertise over those who present a broad but shallow menu of services.

North America remains the dominant geography for cell and gene therapy CDMO activity, estimated by Nexvora to represent roughly 45%–50% of 2025 global market revenue. The region's leadership reflects a combination of factors: the concentration of innovative biotech sponsors in the United States, the maturity of the FDA's regulatory framework for gene therapy and advanced therapy medicinal products, the depth of venture and institutional capital that has funded both sponsor companies and CDMO capacity expansion, and the presence of major academic medical centers that serve as clinical trial sites and translational research partners. These structural advantages are durable and are unlikely to be displaced in the near term.

Europe holds a meaningful second position, supported by the EMA's advanced therapy medicinal product framework and a strong concentration of CDMO investment in the United Kingdom, Germany, and the Benelux region. However, Nexvora's modeled projections position Asia-Pacific as the fastest-growing region through 2032. This growth is driven by a maturing domestic biotech sector in China, South Korea, and Japan; increasing government investment in cell and gene therapy manufacturing infrastructure; and a growing pool of clinical-stage programs that will need local or regionally proximate manufacturing support. For global CDMO players, Asia-Pacific represents both a market expansion opportunity and a potential source of competitive pressure as local CDMOs build capability.

The regional distribution of demand has important implications for how global CDMOs think about their facility footprints and partnership strategies. Programs seeking simultaneous regulatory approval in the US, EU, and major Asia-Pacific markets require manufacturing solutions that can satisfy multiple regulatory frameworks without duplicating the entire production process. CDMOs with multi-site networks and proven experience in regulatory harmonization — particularly around comparability and technology transfer across sites — are increasingly valued by sponsors with global commercial ambitions.

One of the clearest strategic trends identified in Nexvora's market intelligence is the accelerating preference among sponsors for integrated CDMO relationships that span the full manufacturing value chain. At its most comprehensive, this means a single CDMO partner managing plasmid DNA production, viral vector manufacturing, cell processing and expansion, analytical method development and validation, quality release testing, regulatory documentation support, and fill-finish operations. The appeal from a sponsor perspective is straightforward: fewer handoffs, cleaner accountability, simpler governance, and a reduced risk that a technology transfer failure between vendors becomes a clinical or commercial supply crisis.

But integration carries its own risks and requirements. A CDMO that markets itself as fully integrated but relies on a patchwork of subcontractors, affiliate arrangements, or recently acquired capabilities that have not been operationally unified is offering the appearance of integration without the substance. Nexvora's assessment is that the CDMOs gaining the most durable market share are those that have made patient, capital-intensive investments in building genuine internal capability across multiple service pillars — and that can demonstrate this capability through regulatory submission track records, audit outcomes, and the depth of their scientific staff rather than through brochure claims.

For sponsors evaluating integrated CDMO models, Nexvora recommends prioritizing operational accountability structures over service catalog breadth. Key questions should include: Does the CDMO maintain a single quality management system across all service areas, or are quality systems fragmented by acquisition history? Is there a designated program manager with genuine authority to coordinate across internal teams, or does the sponsor de facto manage cross-functional coordination themselves? How has the CDMO handled lifecycle changes — process improvements, site transfers, scale-up — for existing commercial clients, and what was the impact on comparability and supply continuity? The answers to these questions reveal far more about a CDMO's true integration capability than any sales presentation.

As the cell and gene therapy CDMO market matures and capacity constraints ease in certain service areas, the basis of competition is evolving. Price and availability — once dominant selection criteria during periods of genuine supply scarcity — are giving way to a more sophisticated set of differentiators that reflect the commercial-era demands of sponsors and the heightened expectations of regulators. Nexvora's view is that strategic differentiation will increasingly depend on five interconnected capabilities: batch reliability, regulatory maturity, assay depth, technology transfer execution, and lifecycle change management.

Batch reliability is arguably the foundation of everything else. A CDMO that delivers consistently high batch success rates across a large production history is demonstrating mastery of the process variables that most frequently undermine cell and gene therapy manufacturing — vector titer, viability, potency, sterility, and yield. Regulatory maturity means not just a clean audit history, but a demonstrated ability to engage proactively with agencies, anticipate emerging guidance, and prepare submission-ready documentation without requiring extensive sponsor remediation. Assay depth reflects the CDMO's internal capacity to develop, validate, and execute the complex, often bespoke analytical methods that cell and gene therapy products require — a capability that cannot be easily outsourced without introducing coordination risk.

Technology transfer execution and lifecycle change management are perhaps the least glamorous but most commercially consequential differentiators. The ability to receive a process from a sponsor or prior CDMO and reproduce it faithfully — on schedule, within specification, and without sacrificing batch success rates — is a genuine organizational capability that requires experienced technical transfer teams, robust documentation systems, and a culture of scientific rigor. Similarly, the ability to implement process improvements, address regulatory requests, or execute site transfers without triggering prolonged comparability discussions or supply interruptions separates CDMOs that are genuinely equipped for long-term commercial partnerships from those that excel in the less demanding clinical-stage environment. As the market moves deeper into its commercial era, these distinctions will determine which CDMOs capture the most durable and valuable positions in sponsor supply chains.